LGALS2 functional variant rs7291467 is not associated with susceptibility to myocardial infarction in Caucasians

Atherosclerosis

Volumn 194, Issue 1, 2007, Pages 112-115

  Mangino, Massimo ^a   Braund, Peter ^a   Singh, Ravi ^a   Steeds, Rick ^b   Thompson, John R ^a   Channer, Kevin ^b   Samani, Nilesh J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

LGALS2; Myocardial infarction

Indexed keywords

GALECTIN 2;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENDER; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; JAPANESE; LGALS2 GENE; MAJOR CLINICAL STUDY; MALE; POWER CALCULATION; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TECHNIQUE; UNITED KINGDOM;

ADULT; AGED; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GALECTIN 2; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREAT BRITAIN; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VARIATION (GENETICS);

EID: 34648846038     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.10.004     Document Type: Article

References (34)

1. Bonow R.O., Smaha L.A., Smith Jr. S.C., Mensah G.A., and Lenfant C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 106 (2002) 1602-1605
2. Marenberg M.E., Risch N., Berkman L.F., Floderus B., and de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330 (1994) 1041-1046
3. Jefferson B.K., and Topol E.J. Molecular mechanisms of myocardial infarction. Curr Probl Cardiol 30 (2005) 333-374
4. Lusis A.J., Mar R., and Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 5 (2004) 189-218
5. Watkins H., and Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 7 (2006) 163-173
6. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
7. Wang L., Fan C., Topol S.E., Topol E.J., and Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 302 (2003) 1578-1581
8. Ozaki K., Ohnishi Y., Iida A., et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32 (2002) 650-654
9. Helgadottir A., Gretarsdottir S., St Clair D., et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 76 (2005) 505-509
10. Lohmussaar E., Gschwendtner A., Mueller J.C., et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 36 (2005) 731-736
11. Kajimoto K., Shioji K., Ishida C., et al. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ J 69 (2005) 1029-1034
12. PROCARDIS C. A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. Eur J Hum Genet 2004;12:770-4.
13. Bhagavatula M.R., Fan C., Shen G.Q., et al. Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Genet 13 (2004) 3181-3188
14. Gonzalez P., Garcia-Castro M., Reguero J.R., et al. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. J Med Genet 43 (2006) 167-169
15. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
16. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
17. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 91 (2003) 3A-6A
18. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
19. Ozaki K., Inoue K., Sato H., et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature 429 (2004) 72-75
20. Steeds R., Adams M., Smith P., Channer K., and Samani N.J. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects. Thromb Haemost 79 (1998) 980-984
21. Brouilette S., Singh R.K., Thompson J.R., Goodall A.H., and Samani N.J. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 23 (2003) 842-846
22. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979;59:607-9.
23. Livak K.J. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14 (1999) 143-149
24. Gauderman W.J. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 21 (2002) 35-50
25. Petersen S., Peto V., Scarbough P., and Rayner M. Coronary heart disease statistics. Br Heart Foundation (2005) 46
26. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
27. Colhoun H.M., McKeigue P.M., and Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 361 (2003) 865-872
28. Guo D., Li M., Zhang Y., et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 36 (2004) 837-841
29. Smyth D.J., Howson J.M., Lowe C.E., et al. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet 37 (2005) 110-111 author reply 2-3
30. Park Y., Park S., Kang J., Yang S., and Kim D. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet 37 (2005) 112 author reply -3
31. Qu H., Bharaj B., Liu X.Q., et al. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet 37 (2005) 111-112 author reply 2-3
32. Jennings C.E., Owen C.J., Wilson V., and Pearce S.H. No association of the codon 55 methionine to valine polymorphism in the SUMO4 gene with Graves' disease. Clin Endocrinol (Oxf) 62 (2005) 362-365
33. Kim T.Y., Park Y.J., Hwang J.K., et al. A C/T polymorphism in the 5′-untranslated region of the CD40 gene is associated with Graves' disease in Koreans. Thyroid 13 (2003) 919-925
34. Heward J.M., Simmonds M.J., Carr-Smith J., et al. A single nucleotide polymorphism in the CD40 gene on chromosome 20q (GD-2) provides no evidence for susceptibility to Graves' disease in UK Caucasians. Clin Endocrinol (Oxf) 61 (2004) 269-272